title: [Gastrectomy with radical D2 lymph node excision--effective and economically standardized therapy of adenocarcinoma of the stomach].
abstract: In a retrospective single center study, the impact of radical D2-lymph adenectomy and splenectomy on operativ course, morbidity, mortality and long-term survival, in 243 patients who underwent radical surgical therapy for gastric cancer, was analyzed. D2-lymph node dissection during gastrectomy or gastric resection did not influence blood loss, artificial respiration time, ICU days or surgical morbidity, whereas splenectomy correlated with a higher hospital mortality, leakage and abscess rate. Due to routinely performed D2-lymphadenectomy long term survival rate (5 years) was 40.6% for all (in detail: 96% in stage IA; 68.5%/IB; 61.2%/II; 35.8%/IIIA; 17.3%IIIB; and 2.6% in stage IV and 58.1% for curative resected patients.
authors.affiliation: Klinik für Allgemeine Chirurgie und Thoraxchirurgie, Kliniken der Christian-Albrechts-Universität Kiel.
authors.forename: A
authors.initials: A
authors.lastname: Schmid
authors.forename: A
authors.initials: A
authors.lastname: Thybusch
authors.forename: D
authors.initials: D
authors.lastname: Henne-Bruns
authors.forename: B
authors.initials: B
authors.lastname: Kremer
mesh_terms: D000230:Adenocarcinoma / Q000191:economics* / Q000401:mortality / Q000601:surgery; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D003362:Cost-Benefit Analysis; D003422:Critical Care / Q000191:economics; D005260:Female; D005743:Gastrectomy / Q000191:economics*; D006801:Humans; D008197:Lymph Node Excision / Q000191:economics*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000191:economics / Q000401:mortality; D011379:Prognosis; D012189:Retrospective Studies; D013156:Splenectomy / Q000191:economics; D013274:Stomach Neoplasms / Q000191:economics* / Q000401:mortality / Q000601:surgery; D015996:Survival Rate
vernacular_title: Gastrektomie mit radikaler D2-Lymphadenektomie--effiziente und ökonomische Standardtherapie bei Adenokarzinomen des Magens.